

Serial No.: 09/995,793

I hereby declare that all statements made herein of my own knowledge are true and that all statements were made on information and belief and are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

10 June 2002

Teresa Stanek Rea  
Registration No. 30,427



#12

Patent  
Attorney's Docket No. 033488-001.001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Bernard H.F. WEBER et al.

Application No.: 09/995,793

Filed: November 29, 2001

For: Novel Retina-Specific Human Proteins  
C7orf9, C12orf7, MPPR and F379

Group Art Unit: 1645

Examiner: Unassigned

Confirmation No.: 9153

TECH CENTER 1600/2900

JUN 13 2002

RECEIVED

INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.


- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$\_\_\_\_\_ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER &amp; MATHIS, L.L.P.

By:

  
Teresa Stanek Rea  
Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: June 10, 2002



Patent  
Attorney's Docket No. 033488-001.001

TECH CENTER 1600/2900

JUN 13 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of )  
Bernard H.F. WEBER *et al.* ) Group Art Unit: 1645  
Application No.: 09/995,793 ) Examiner: Unassigned  
Filed: November 29, 2001 ) Confirmation No.: 9153  
For: NOVEL RETINA-SPECIFIC HUMAN )  
PROTEINS C7orf9, C12orf7, MPP4 )  
AND F379 )

### INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or statement is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.


By: \_\_\_\_\_

Teresa Stanek Rea  
Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: June 10, 2002

(05/02)



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTATTORNEY'S DKT NO.  
033488-001.001APPLICATION NO.  
09/995,793APPLICANT  
Bernard H.F. WEBER  
FILING DATE  
November 29, 2001

GROUP

TECH CENTER 1600-2870

JUN 13 2002

RECEIVED

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
	3,817,837		Rubenstein et al.	6/18/1974
	3,850,752		Schuurs et al.	11/26/1974
	3,939,350		Kronick et al.	2/17/1976
	3,996,345		Ullman et al.	12/7/1976
	4,227,437		Inloes et al.	10/14/1980
	4,275,149		Litman et al.	6/23/1981
	4,366,241		Tom et al.	12/28/1982
	4,816,567		Cabilly et al.	3/28/1989

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
	EP 0 237 362		EUROPE	10/21/1998		
	WO 94/29469		PCT	12/22/1994		
	WO 97/00957		PCT	1/9/1997		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Schuler, Mol. Med., (1997), Vol. 75, pp. 694-698
	Smith et al., Gene, (1998), Vol. 67, pp. 31-40
	Melani, Cancer Res., (1991), Vol. 51, pp. 2897-2901
	Jensen, Biochemistry, (1997), Vol. 36, pp. 5072-5077
	Gotoh, Rinsho Byori, (1997), Vol. 45, pp. 224-228
	Weiler, Nucleic Acids Research, (1997), Vol. 25, pp. 2792-2799
	Koch, J. Pept. Res., (1997), Vol. 49, pp. 80-88
	Finn, Nucleic Acids Research, (1996), Vol. 24, pp. 3357-3363
	Veselkov, Nature, (1996), Vol. 379, page 214
Examiner Signature	Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

 ATTORNEY'S DKT NO.  
033488-001.001

 APPLICATION NO.  
09/995,793

 APPLICANT  
Bernard H.F. WEBER

 FILING DATE  
November 29, 2001

GROU... JUN 13 2002

 RECEIVED  
TECH CENTER 1600/2902

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Bohler, Nature, (1995), Vol. 376, pp. 578-581
	Jalkanen et al., J. Cell. Biol., (1985), Vol. 101, pp. 976-985
	Jalkanen et al., J. Cell. Biol., (1987), Vol. 105, pp. 30B7-3096
	Sobol et al., Clin. Immunopathol., (1982), Vol. 24, pp. 139-144
	Sobol et al., Cancer, (1985), Vol. 65, pp. 2005-2010
	Kohler et al., Nature, (1975), Vol. 256, pp. 495-497
	Wahl et al., J. Nucleic Med., (1983), Vol. 24, pp. 316-325
	Lee, Nucleic Acids Research, (1979), Vol. 6, pg. 3073
	Cooney, Science, (1988), Vol. 241, pp. 456-459
	Dervan, Science, (1991), Vol. 251, pp. 1360-1363
	Zimmermann et al., Neuron, (1994), Vol. 12, pp. 11-24
	Vidal et al., EMBO Journal, (1990), Vol. 9, pp. 833-840
	Mayford et al., Cell, (1995), Vol. 81, pp. 891-904
	Pinkert et al., Genes & Dev., (1987), Vol. 1, pp. 268-276
	Mantero et al., Clinical Chemistry, (1991), Vol. 37, pp. 422-429
	Gossen and Bujard, Proc. Natl. Acad. Sci. USA, (1992), Vol. 89, pp. 5547-5551
	Gossen and Bujard, Trends Biotech, (1994), Vol. 12, pp. 58-62
	Chomczynski and Sacchi, Anal. Biochem., (1987), Vol. 162, pp. 156-159
	Church and Gilbert, PNAS USA, (1984), Vol. 81, pp. 1991-1995
	Anderson, Curr. Biol., (1996), Vol. 6, pp. 382-384
	Frohman et al., PNAS USA, (1988), Vol. 85, pp. 8998-9002
	Trask et al., Human Molecular Genet., (1998), Vol. 9, pp. 1337-1345
Examiner Signature	Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.